1. Home
  2. ZLAB vs FBIZ Comparison

ZLAB vs FBIZ Comparison

Compare ZLAB & FBIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • FBIZ
  • Stock Information
  • Founded
  • ZLAB 2013
  • FBIZ 1909
  • Country
  • ZLAB Cayman Islands
  • FBIZ United States
  • Employees
  • ZLAB N/A
  • FBIZ N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • FBIZ Major Banks
  • Sector
  • ZLAB Health Care
  • FBIZ Finance
  • Exchange
  • ZLAB Nasdaq
  • FBIZ Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • FBIZ N/A
  • IPO Year
  • ZLAB 2017
  • FBIZ N/A
  • Fundamental
  • Price
  • ZLAB $33.80
  • FBIZ $49.93
  • Analyst Decision
  • ZLAB Buy
  • FBIZ Strong Buy
  • Analyst Count
  • ZLAB 4
  • FBIZ 4
  • Target Price
  • ZLAB $47.37
  • FBIZ $58.75
  • AVG Volume (30 Days)
  • ZLAB 1.7M
  • FBIZ 27.9K
  • Earning Date
  • ZLAB 05-08-2025
  • FBIZ 04-24-2025
  • Dividend Yield
  • ZLAB N/A
  • FBIZ 2.32%
  • EPS Growth
  • ZLAB N/A
  • FBIZ 20.00
  • EPS
  • ZLAB N/A
  • FBIZ 5.20
  • Revenue
  • ZLAB $398,988,000.00
  • FBIZ $144,630,000.00
  • Revenue This Year
  • ZLAB $45.57
  • FBIZ $17.65
  • Revenue Next Year
  • ZLAB $47.91
  • FBIZ $9.14
  • P/E Ratio
  • ZLAB N/A
  • FBIZ $9.61
  • Revenue Growth
  • ZLAB 49.59
  • FBIZ 6.57
  • 52 Week Low
  • ZLAB $15.05
  • FBIZ $33.00
  • 52 Week High
  • ZLAB $39.77
  • FBIZ $56.46
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 54.59
  • FBIZ 60.75
  • Support Level
  • ZLAB $28.34
  • FBIZ $45.92
  • Resistance Level
  • ZLAB $34.59
  • FBIZ $51.36
  • Average True Range (ATR)
  • ZLAB 2.28
  • FBIZ 2.04
  • MACD
  • ZLAB 0.42
  • FBIZ 0.57
  • Stochastic Oscillator
  • ZLAB 89.01
  • FBIZ 84.42

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: